Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

104.56 -1.07 (-1.01%)
Streaming Delayed Price Updated: 12:17 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,358,438
Open 105.58
Bid (Size) 104.55 (2)
Ask (Size) 104.57 (3)
Prev. Close 105.63
Today's Range 103.72 - 105.60
52wk Range 96.36 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.79%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Double Flops For Merck's Lung Cancer Studies
Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer (NSCLC)... 
Via Benzinga
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-5.92%
-5.92%
1 Month
+0.21%
+0.21%
3 Month
-1.81%
-1.81%
6 Month
-3.73%
-3.73%
1 Year
-4.01%
-4.01%

More News

Read More
5 Dividend Stocks That Recently Increased Their Payouts
Via The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
Via Talk Markets
Price Over Earnings Overview: Merck & Co
Via Benzinga
Analyst Ratings for Merck & Co
Via Benzinga
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
From Amazon.com, Inc.
Via Business Wire
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Announces First-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Via Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
Via InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
Via Benzinga
Merck to Acquire Caraway Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Three Solid Stocks That Still Have Plenty Of Growth Left
Via Talk Markets
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
Via Benzinga
Exposures Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
Via Benzinga
Exposures Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Via Benzinga
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.